BioXcel Therapeutics

BioXcel Therapeutics, Inc. is a biopharmaceutical company based in New Haven, Connecticut, founded in 2017. The company focuses on developing innovative medicines for neuroscience disorders and immuno-oncology by utilizing artificial intelligence and proprietary machine learning algorithms. Their unique approach, known as "drug re-innovation," repurposes existing approved drugs to identify new therapeutic uses, aiming to enhance the efficiency of drug development and improve patient outcomes. BioXcel's clinical-stage product portfolio includes several candidates targeting various neurological and psychiatric conditions. Notable products include IGALMI, a sublingual film for schizophrenia and bipolar disorder, and BXCL501, which addresses multiple disorders such as bipolar disorder and PTSD. The company also has a subsidiary, OnkosXcel Therapeutics, dedicated to developing therapies in immuno-oncology. Since going public in March 2018, BioXcel has raised significant funds to support its clinical pipeline, focusing on delivering meaningful therapeutic benefits to patients with significant unmet medical needs.